Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: Insights from ROCKET AF

William Schuyler Jones, Anne S. Hellkamp, Jonathan Halperin, Jonathan P. Piccini, Gunter Breithardt, Daniel E. Singer, Keith A.A. Fox, Graeme J. Hankey, Kenneth W. Mahaffey, Robert M. Califf, Manesh R. Patel

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

AimsVascular disease is included in a risk scoring system to predict stroke in patients with non-valvular atrial fibrillation (AF). This post hoc analysis of ROCKET AF aimed to determine the absolute rates of stroke and bleeding, and the relative effectiveness and safety of rivaroxaban vs. warfarin in patients with and without peripheral artery disease (PAD). Peripheral artery disease was defined on the case-report form as the presences of intermittent claudication, amputation for arterial insufficiency, vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities, or previously documented abdominal aortic aneurysm.Methods and resultsROCKET AF was a double-blind, double-dummy, randomized-controlled trial comparing rivaroxaban and warfarin for the prevention of stroke or systemic embolism. A total of 839 (5.9%) patients in ROCKET AF had PAD. Patients with and without PAD had similar rates of stroke or systemic embolism [HR: 1.04, 95% CI (0.72, 1.50), P = 0.84] and major or non-major clinically relevant (NMCR) bleeding [HR: 1.11, 95% CI (0.96, 1.28), P = 0.17], respectively. The efficacy of rivaroxaban when compared with warfarin for the prevention of stroke or systemic embolism was similar in patients with PAD (HR: 1.19, 95% CI: 0.63-2.22) and without PAD (HR: 0.86, 95% CI: 0.73-1.02; interaction P = 0.34). There was a significant interaction for major or NMCR bleeding in patients with PAD treated with rivaroxaban compared with warfarin (HR: 1.40, 95% CI: 1.06-1.86) compared with those without PAD (HR: 1.03, 95% CI: 0.95-1.11; interaction P = 0.037).ConclusionPatients with PAD in ROCKET AF did not have a statistically significant higher risk of stroke or systemic embolism than patients without PAD, and there were similar efficacy outcomes in patients treated with rivaroxaban and warfarin. In PAD patients, there was a higher risk of major bleeding or NMCR bleeding with rivaroxaban when compared with warfarin (interaction P = 0.037). Further investigation is warranted to validate this subgroup analysis and determine the optimal treatment in this high-risk cohort of AF patients with PAD. Published on behalf of the European Society of Cardiology. All rights reserved.

Original languageEnglish
Pages (from-to)242-249
Number of pages8
JournalEuropean Heart Journal
Volume35
Issue number4
DOIs
StatePublished - Jan 2014

Keywords

  • Atrial fibrillation
  • Bleeding
  • Peripheral artery disease
  • Rivaroxaban
  • Stroke
  • Systemic embolism

Fingerprint

Dive into the research topics of 'Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: Insights from ROCKET AF'. Together they form a unique fingerprint.

Cite this